688363 华熙生物
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入3,874,744-8.21%6,075,9246,359,1924,947,7742,632,734
减:营业总成本3,419,166-7.48%5,438,2345,322,1934,165,9381,925,485
    其中:营业成本1,010,188-11.13%1,621,0281,463,2271,085,252489,470
               财务费用(7,136)-71.45%(30,795)(48,657)(495)(512)
               资产减值损失(18,154)376.09%(54,403)(15,447)(29,828)(16,257)
公允价值变动收益32-86.39%1,468(143)7,3943,339
投资收益(4,996)-369.49%1,32711,91520,64634,177
    其中:对联营企业和合营企业的投资收益(6,136)322.19%(1,652)(2,360)(344)(5,964)
营业利润436,125-28.64%708,3861,136,314905,553757,048
利润总额436,569-28.48%701,7221,136,112890,199758,898
减:所得税费用77,519-24.99%118,980174,732114,643113,887
净利润359,050-29.19%582,742961,380775,556645,011
减:非控股权益(2,974)-59.36%(9,814)(9,538)(6,779)(828)
股东净利润362,024-29.62%592,556970,919782,335645,839

市场价值指针
每股收益 (元) *0.750-29.91%1.2302.0201.6301.350
每股派息 (元) *----0.3800.6100.4900.410
每股净资产 (元) *14.5711.34%14.41613.78911.87310.458
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容